Tricida (Tricida) Beta : N/A (As of May. 05, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Tricida Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-05-05), Tricida's Beta is Not available.

Tricida Beta Historical Data

The historical data trend for Tricida's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tricida Beta Chart

Tricida Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Beta

Get a 7-Day Free Trial

0.99

Tricida Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Beta	Get a 7-Day Free Trial															1.25	0.99	1.03	0.71	0.56

Competitive Comparison of Tricida's Beta

For the Biotechnology subindustry, Tricida's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tricida's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tricida's Beta distribution charts can be found below:

* The bar in red indicates where Tricida's Beta falls into.

Tricida Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Tricida (OTCPK:TCDAQ) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Tricida Beta Related Terms

Thank you for viewing the detailed overview of Tricida's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.

Tricida (Tricida) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tricida Inc (OTCPK:TCDAQ) » Definitions » Beta

Comparable Companies

Traded in Other Exchanges

N/A

Address

7000 Shoreline Court, Suite 201, South San Francisco, CA, USA, 94080

Website

https://www.tricida.com

Tricida Inc is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal, or GI, tract. The primary area of focus is to slow the progression of chronic kidney disease through the treatment of metabolic acidosis.

Executives

David P Bonita	director, 10 percent owner	C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Robert J Alpern	director	YALE SCHOOL OF MEDICINE, 333 CEDAR STREET, C203 SHM, NEW HAVEN CT 06520
Venrock Healthcare Capital Partners Ii, L.p.	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Sibling Capital Fund Ii-b L.p.	10 percent owner, other: *possible member of 10% group	2033 6TH AVE, SUITE 330, SEATTLE WA 98121
Sibling Capital Ventures Ii Llc	10 percent owner, other: *possible member of 10% group	2033 6TH AVE, SUITE 330, SEATTLE WA 98121
Brian M. Isern	10 percent owner, other: *possible member of 10% group	2033 6TH AVE., SUITE 330, SEATTLE WA 98121
Sibling Capital Fund Ii-c L.p.	10 percent owner, other: *possible member of 10% group	2033 6TH AVE, SUITE 330, SEATTLE WA 98121
Sibling Capital Ventures Iii Llc	10 percent owner, other: *possible member of 10% group	2033 6TH AVE, SUITE 330, SEATTLE WA 98121
Sibling Capital Fund Ii-a L.p.	10 percent owner, other: possible member of 10% group	500 YALE AVE N, SEATTLE WA 98109
Vhcp Management Eg, Llc	10 percent owner	3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Healthcare Capital Partners Eg, L.p.	10 percent owner	3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Vhcp Co-investment Holdings Iii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Management Iii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Venrock Healthcare Capital Partners Iii, L.p.	10 percent owner	530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036